circle

INVESTORS & MEDIA

PRESS RELEASES

  • Webcast
    X Cytokinetics, Inc. Annual Shareholder Meeting
    May 13, 2020 10:30 AM PDT

    Cytokinetics, Inc. Annual Shareholder Meeting
    May 13, 2020 10:30 AM PDT
  • Webcast
    X Q1 2020 Cytokinetics, Inc. Earnings Conference Call
    May 6, 2020 4:30 PM EDT

    Q1 2020 Cytokinetics, Inc. Earnings Conference Call
    May 6, 2020 4:30 PM EDT
Date Title and Summary
Toggle Summary FDA Grants Fast Track Designation For Omecamtiv Mecarbil In Heart Failure
Fast Track Designation Highlights the Urgent Need for New Heart Failure Treatment Options THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. , May 8, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the U.S.
Toggle Summary Cytokinetics to Hold Annual Meeting of Stockholders
SOUTH SAN FRANCISCO, Calif. , May 07, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 13, 2020 at 10:30 AM Pacific Time at the Company’s headquarters, 280 East Grand Avenue , South San
Toggle Summary Cytokinetics Reports First Quarter 2020 Financial Results
Top-line Results for GALACTIC-HF Expected in Q4 2020 Ended Q1 with More Than Two Years of Going Forward Cash Based on 2020 Guidance SOUTH SAN FRANCISCO, Calif. , May 06, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the first quarter of 2020.
Toggle Summary Cytokinetics to Announce First Quarter Results on May 6, 2020
SOUTH SAN FRANCISCO, Calif. , April 22, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 6, 2020 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a conference
Toggle Summary Cytokinetics Provides Clinical Trials and Business Update in Response to COVID-19 Pandemic
Top-line Results for GALACTIC-HF Expected in Q4 2020; Enrollment in METEORIC-HF Temporarily Suspended SOUTH SAN FRANCISCO, Calif. , April 14, 2020 (GLOBE NEWSWIRE) -- Cytokinetics , Incorporated (Nasdaq: CYTK) today provided an update regarding the company's clinical trials and business operations
Toggle Summary Cytokinetics to Participate in the 19th Annual Needham Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , April 08, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the 19 th Annual Needham Virtual Healthcare Conference on
Toggle Summary Correction: Cytokinetics Announces Baseline Characteristics from GALACTIC-HF at ACC.20/WCC Virtual
Top-line Results for GALACTIC-HF Expected in Q4 2020 SOUTH SAN FRANCISCO, Calif. , March 30, 2020 (GLOBE NEWSWIRE) -- In the press release published at 7:30 AM ET on March 30, 2020 , due to a newswire service error, the quotation from John Teerlink , M.D., was omitted.
Toggle Summary Cytokinetics to Announce Baseline Characteristics from GALACTIC-HF During ACC.20/WCC
SOUTH SAN FRANCISCO, Calif. , March 20, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that patient baseline characteristics and demographics from GALACTIC-HF ( G lobal A pproach to L owering A dverse C ardiac Outcomes T hrough I mproving C ontractility in H eart
Toggle Summary Cytokinetics Granted European Orphan Designation for Reldesemtiv for the Treatment of Amyotrophic Lateral Sclerosis
SOUTH SAN FRANCISCO, Calif. , March 04, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the European Medicines Agency (EMA) has granted orphan medicinal product designation to reldesemtiv for the treatment of amyotrophic lateral sclerosis (ALS).
Toggle Summary Cytokinetics Reports Fourth Quarter 2019 Financial Results
GALACTIC-HF Continuing Following Second Planned Interim Analysis;  Top-line Results for GALACTIC-HF Expected in Q4 2020 Company Provides 2020 Financial Guidance; More Than Two Years of Cash Runway Based on 2020 Guidance SOUTH SAN FRANCISCO, Calif. , March 03, 2020 (GLOBE NEWSWIRE) -- Cytokinetics,
Toggle Summary Cytokinetics Announces Preclinical Data for AMG 594 Presented at the Keystone Symposium on Heart Failure
In Vitro Studies Demonstrate Cardiac Troponin Activator Selectively Activates Cardiac Muscle Fibers with Little Effect on Slow Skeletal Muscle or Fast Skeletal Muscle Expect to Complete SAD/MAD Phase 1 Study of AMG 594 in 2H 2020 SOUTH SAN FRANCISCO, Calif.
Toggle Summary Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
SOUTH SAN FRANCISCO, Calif. , Feb. 28, 2020 (GLOBE NEWSWIRE) -- Cytokinetics , Incorporated (Nasdaq: CYTK) today announced that on February 29 it is joining the European Organisation for Rare Diseases (EURORDIS) and the National Organization for Rare Disorders (NORD) to recognize Rare Disease Day®,
Toggle Summary Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis
Data Monitoring Committee Recommends Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Heart Failure Continue without Changes Topline Results Expected in Q4 2020 THOUSAND OAKS, Calif. , SOUTH SAN FRANCISCO, Calif. , and SURESNES, France, Feb.
Toggle Summary Cytokinetics Announces Preclinical Data for CK-3773274 Presented at the Biophysical Society 64th Annual Meeting
Preclinical Studies Demonstrate Distinct Binding Site for Next-Generation Cardiac Myosin Inhibitor SOUTH SAN FRANCISCO, Calif. , Feb. 20, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that preclinical data related to CK-3773274 (CK-274) were presented at the
Toggle Summary Cytokinetics to Announce Fourth Quarter Results on March 3, 2020
SOUTH SAN FRANCISCO, Calif. , Feb. 18, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on March 3, 2020 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a
Toggle Summary Cytokinetics Announces Publication Relating to Design of GALACTIC-HF, a Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
Second Interim Analysis in GALACTIC-HF Expected to Occur in Q1 2020 Topline Results Expected in Q4 2020 SOUTH SAN FRANCISCO, Calif. , Feb. 06, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the publication of a manuscript relating to the design of GALACTIC-HF ( G
Toggle Summary Cytokinetics Announces Recipients of Second Annual Communications Fellowship Grants
Total of $100,000 Awarded to Five Organizations to Support Communications and Community Outreach SOUTH SAN FRANCISCO, Calif. , Jan. 22, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today announced the recipients of its Communications Fellowship Grant program, an annual grant program
Toggle Summary Cytokinetics Announces Vision 2025 and Outlines 2020 Corporate Milestones
Top-line Results from GALACTIC-HF Now Expected in Q4 2020; Commercial Readiness Underway REDWOOD-HCM Initiated; Second Cardiac Myosin Inhibitor Planned to Enter Clinic in 1H 2020 SOUTH SAN FRANCISCO, Calif. , Jan. 13, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Inc.
Toggle Summary Cytokinetics Announces Start of REDWOOD-HCM, a Phase 2 Clinical Trial of CK-3773274
Next-Generation Cardiac Myosin Inhibitor Advances In Clinical Trial Designed to Assess Effects Using Two-Week Dose Titration Schedule SOUTH SAN FRANCISCO, Calif. , Jan. 06, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that REDWOOD-HCM ( R andomized E valuation